[Treatment of hepatosplenic candidiasis with liposomal amphotericin B in a patient with acute leukemia; a case report of the experience of use of liposomal amphotericin B].
We report a 26-year-old male patient with acute myelocytic leukemia and hepatosplenic candidiasis during his clinical course. His hepatosplenic candidiasis was refractoty to itraconazole and fluconazol. He developed serious side-effect such as renal dysfunction, when conventional amphotericin B was given. Then he was treated with liposomal amphotericin B (Abelcet). This therapy was safe and effective for him. He was able to be treated with 3075 mg of a liposomal amphotericin B. This was ten times as much as the dose of conventional amphotericin B which was given earlier until amphotericin B was stopped because of renal dysfunction. Liposomal amphotericin B seems to be a safe and effective therapy for systemic fungal infectin and should be considered more in Japan.
Hasegawa
T
T
Department of Laboratory Medicine, Osaka City University Medical School, Japan.
Hiyoshi
M
M
Aoyama
Y
Y
Sakamoto
C
C
Ohta
K
K
Yamane
T
T
Hino
M
M
Tatsumi
N
N
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage*; D000935:Antifungal Agents / Q000008:administration & dosage*; D002177:Candidiasis / Q000188:drug therapy*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications*; D008081:Liposomes; D008100:Liver Abscess / Q000188:drug therapy*; D008297:Male; D013158:Splenic Diseases / Q000188:drug therapy*
D000935:Antifungal Agents; D008081:Liposomes; D000666:Amphotericin B